- Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin-stabilizing factor. J Clin Invest 1980;65 (2): 290–297.
- Ratnoff OD, Steinberg AG. Fibrin cross-linking and heredity. Ann N Y Acad Sci 1972;202: 186–189.
- Henriksson P, McDonagh J, Villa M. Type I autoimmune inhibitor of factor XIII in a patient with congenital factor XII deficiency [abstract]. Thromb Haemost 1983;50 (1): 272.
- Fiore PA, Ellis LD, Dameshek HL, Lewis JH. XIII inhibitor and antituberculosis therapy [abstract]. Clin Res 1971;19–418.
- Nakamura S, Kato A, Sakata Y, Aoki N. Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide. Br J Haematol 1988;68 (3): 313–319.
- Graham JE, Yount WJ, Roberts HR. Immunochemical characterization of a human antibody to factor XIII. Blood 1973;41 (5): 661–669.
- Fickenscher K, Aab A, Stuber W. A photometric assay for blood coagulation factor XIII. Thromb Haemost 1991;65 (5): 535–540.
- Lorand L. Fibrinoligase: the fibrin-stabilizing factor system of blood plasma. Ann N Y Acad Sci 1972;202: 6–30.
- Lorand L. Hemorrhagic disorders of fibrin stabilization. In Ogston D, Bennett B, eds. Hemostasis: Biochemistry, Physiology and Pathology. London: John Wiley & Sons Ltd, 1977: 405–423.
- Otis PT, Feinstein DI, Rapaport SI, Patch MJ. An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations. Blood 1974;44 (6): 771–781.
- Krumdieck R, Shaw DR, Huang ST, Poon MC, Rustagi PK. Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenström's macroglobulinemia. Am J Med 1991;90 (5): 639–645.
- Lopaciuk S, Bykowska K, McDonagh JM, McDonagh RP, Yount WJ, Fuller CR, Cooperstein L, Gray A Jr, Lorand L. Difference between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. J Clin Invest 1978;61 (5): 1196–1203.
- McDevitt NB, McDonagh J, Taylor HL, Roberts HR. An acquired inhibitor to factor XIII. Arch Intern Med 1972;130 (5): 772–777.
- Milner GR, Holt PJ, Bottomley J, Maciver JE. Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII. J Clin Pathol 1977;30 (8): 770–773.
- Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83 (2): 435–445.
- Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101 (10): 3857–3861.
- Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98 (4): 952–957.
- Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002;100 (9): 3426–3428.
- Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004;103 (12): 4424–4428.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 19, 2006 - Issue 3